Skip to site content
U.S. Department of Health and Human Services
Division of Diabetes Treatment and Prevention (DDTP)

Helping Your Patients with Diabetes Slowing the Progression of DKD in T2D; Part 2: Treatment

Quiz for CE Credit

This quiz consists of multiple choice questions with one correct answer.
Please select one answer for each question, then click the Submit Answers button at the end of the quiz.

 
1. Treatment of DKD (diabetic kidney disease) can slow decline in GFR from an average of 12 ml/min/year to an average of 2-4 ml/min/year.


 
2. The new ADA (American Diabetes Association) Standard regarding treatment goal for albuminuria states that patients with diabetes and urinary albumin >300 mg/g Cr and/or an estimated GFR 30-60 ml/min, urinary albumin and estimated eGFR should be monitored at least twice annually to guide therapy.


 
3. Small elevations of serum creatinine can occur 3-5 days after the start of ACEI or ARB therapy, and are not to be confused with acute kidney injury.


 
4. At any eGFR, the degree of albuminuria is associated with risk of:




 
5. KDIGO guidelines for clinicians caring for patients with diabetes and CKD (not receiving dialysis) should be monitored with an A1C target range from less than 6.5-8.0%, depending on risk of hypoglycemia.


 
6. Patients with moderate CKD (eGFR between 30-45) are not candidates for initiation of metformin, but patients currently on metformin may continue cautiously.


 
7. ADA recommends SGLT2 inhibitors be given to all patients with CKD stage 3 or higher regardless of glycemic control, as it has been shown they slow the progression of CKD and reduce the risk of heart failure, independent of glycemic control.


 
8. The ADA Standards of Care in regards to ACE and ARB treatment state:




 
9. For patients (not on dialysis) for CKD stage 3 or higher, dietary protein intake should be a maximum of 0.8g/kg body weight per day.